| Preclinical efficacy of anti-RON antibody–drug conjugate Zt/g4-MMAE for targeted therapy of pancreatic cancer overexpressing RON receptor tyrosine kinase HP Yao, L Feng, TH Weng, CY Hu, SR Suthe, AGM Mostofa, LH Chen, ... Molecular Pharmaceutics 15 (8), 3260-3271, 2018 | 22 | 2018 |
| RON receptor tyrosine kinase as a therapeutic target for eradication of triple-negative breast cancer: efficacy of anti-RON ADC Zt/g4-MMAE SR Suthe, HP Yao, TH Weng, CY Hu, L Feng, ZG Wu, MH Wang Molecular Cancer Therapeutics 17 (12), 2654-2664, 2018 | 20 | 2018 |
| Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy XM Tong, L Feng, SR Suthe, TH Weng, CY Hu, YZ Liu, ZG Wu, MH Wang, ... Journal for immunotherapy of cancer 7, 1-15, 2019 | 19 | 2019 |
| Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer … HP Yao, L Feng, SR Suthe, LH Chen, TH Weng, CY Hu, ES Jun, ZG Wu, ... Journal for ImmunoTherapy of Cancer 7, 1-16, 2019 | 18 | 2019 |
| Antibody–drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer HP Yao, SR Suthe, R Hudson, MH Wang Drug discovery today 25 (7), 1160-1173, 2020 | 8 | 2020 |
| Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials HP Yao, SR Suthe, XM Tong, MH Wang Therapeutic advances in medical oncology 12, 1758835920920069, 2020 | 3 | 2020 |
| Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability Y Feng, J Lee, L Yang, MB Hilton, K Morris, S Seaman, VVSR Edupuganti, ... Cell reports 42 (12), 2023 | 2 | 2023 |
| RON receptor tyrosine kinase in tumorigenic stemness as a therapeutic target of antibody-drug conjugates for eradication of triple-negative breast cancer stem cells SR Suthe, HP Yao, TH Weng, MH Wang Current Cancer Drug Targets 23 (2), 103-117, 2023 | 2 | 2023 |
| Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase R Hudson, HP Yao, SR Suthe, D Patel, MH Wang Current Cancer Drug Targets 22 (4), 312-327, 2022 | 2 | 2022 |
| Correction to: Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine … HP Yao, L Feng, SR Suthe, LH Chen, TH Weng, CY Hu, ES Jun, ZG Wu, ... Journal for ImmunoTherapy of Cancer 7, 2019 | 2 | 2019 |
| RON-targeted antibody-drug conjugate therapy eliminates cancer stem-like cells and induces long-term tumor regressions in preclinical models of triple-negative breast cancer. SR Suthe, HP Yao, MH Wang CANCER IMMUNOLOGY RESEARCH 8 (4), 108-108, 2020 | | 2020 |
| RON Receptor‐Targeted Antibody‐Drug Conjugate Therapy Ablates Cancer Stem Cells and Induces Long‐term Tumor Regressions in Preclinical Models of Triple‐Negative Breast Cancer … SR Suthe, HP Yao, ming‐hai wang The FASEB Journal 33 (S1), 510.3-510.3, 2019 | | 2019 |
| RON-Targeted Antibody-Drug Conjugate Therapy Ablates Cancer Stem Cells and Induces Longterm Tumor Regressions in Preclinical Models of Triple Negative Breast Cancer S Suthe, H Yao, M Wang AMERICAN JOURNAL OF PATHOLOGY 188 (10), 2411-2412, 2018 | | 2018 |
| Development of a novel ron receptor targeted antibody-drug conjugates using cysteine bridging technology for potential treatment of pancreatic cancer SR Suthe, HP Yao, PC Trippier, MH Wang Cancer Research 78 (13_Supplement), 745-745, 2018 | | 2018 |
| Reduced RON Expression, DM1 resistance and MRP1 Upregulation Contributes to Resistance in Colon Cancer Cells against anti‐RON Antibody‐Drug Conjugate Zt/g4‐DM1 SR Suthe, HP Yao, ming‐hai wang The FASEB Journal 32, 281.10-281.10, 2018 | | 2018 |
| Development of A Novel RON Targeted Antibody‐Drug Conjugates using Cysteine Bridging Technology for Potential Treatment of Pancreatic Cancer SR Suthe, HP Yao, paul c trippier, ming‐hai wang The FASEB Journal 32, 807.7-807.7, 2018 | | 2018 |
liang fengTexas Tech University Health Science CenterVerified email at ttuhsc.edu
